David Wild
Reporter
Latest From David Wild
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.
A GenAI Copilot For The Regulatory Affairs Team
A GenAI copilot for biopharma regulatory requirements could yield significant returns.
Gene Therapy’s Next Target: Our Microbes
CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years.
Once Destined For Pro Rodeo, Women’s Health CEO Rides A Different Horse
2024 In Vivo Rising Leader Somer Baburek wants to overhaul how endometriosis is diagnosed and managed with a product that she says has billion-dollar potential.
Jazz’s CNS Pipeline Demonstrates Transformation
With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.